Oppenheimer & Co. Inc. Increases Stake in Pfizer Inc. (NYSE:PFE)

Oppenheimer & Co. Inc. lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 9.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 636,215 shares of the biopharmaceutical company's stock after purchasing an additional 54,844 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Pfizer were worth $16,122,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tallon Kerry Patrick bought a new stake in Pfizer during the fourth quarter valued at approximately $509,000. Brighton Jones LLC lifted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. Redmond Asset Management LLC bought a new position in Pfizer in the fourth quarter valued at $480,000. Finally, Callan Capital LLC raised its position in Pfizer by 7.2% during the fourth quarter. Callan Capital LLC now owns 17,945 shares of the biopharmaceutical company's stock valued at $476,000 after purchasing an additional 1,209 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on PFE. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Trading Up 0.2%

Pfizer stock traded up $0.04 during trading hours on Thursday, reaching $24.30. The stock had a trading volume of 31,721,433 shares, compared to its average volume of 41,295,326. The company has a fifty day simple moving average of $23.42 and a 200-day simple moving average of $24.85. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a market cap of $138.18 billion, a PE ratio of 17.61, a PEG ratio of 0.88 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.08%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.